Aeglea BioTherapeutics to reduce headcount to 10, seek strategic alternatives
Aeglea BioTherapeutics rolled out interim data for its drug for a rare inherited disorder, but said it doesn’t support a pivotal trial design as the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
